Phase 2 Startnegative~month

Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int

Name: Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int
Start: 2030-01-01

January 1, 2030

Company: LISATA THERAPEUTICS, INC. (LSTA)
Drug: single
Indication: PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int — LSTA Phase 2 Start | BioSniper